Cardiac & Renal Outcomes with Efpeglenatide in Diabetes (AMPLITUDE-O) | NEJM | Med Journal Club скачать в хорошем качестве

Cardiac & Renal Outcomes with Efpeglenatide in Diabetes (AMPLITUDE-O) | NEJM | Med Journal Club

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes AMPLITUDE-O Published online in the New England Journal of Medicine on June 28, 2021 Presented in the American Diabetes Association (ADA) 81st Scientific Sessions on June 29, 2021 Article link: https://www.nejm.org/doi/full/10.1056... DOI: 10.1056/NEJMoa2108269 Funded by Sanofi ClinicalTrials.gov Number: NCT03496298 Another trial on Semaglutide: Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)    • Tirzepatide versus Semaglutide in Type 2 D...   https://www.nejm.org/doi/full/10.1056... DOI: 10.1056/NEJMoa2107519 Timestamps 0:00 - Opening 0:23 - Introduction 0:39 - Background 3:09 - Study Design 4:16 - Outcomes 4:38 - Results 5:56 - Discussion DISCLAIMER THIS VIDEO IS NOT CONSIDERED MEDICAL ADVICE. The information, including but not limited to, text, graphics and images are for educational purposes only, and is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care professional regarding any queries, and never disregard professional medical advice or delay in seeking it because of something you have read, watched, or listened to on this video, or any other videos, reports, texts, tweets or other sources.